NBP
NovaBridge Biosciences
Biotechnology
Market Cap$416M
5Y Perf.-91.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NBP vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-58.8%
NBP vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NBP | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $416M | $1712.35T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-25M | $-168M |
| Total Debt | $4M | $22M |
| Cash & Equiv. | $68M | $194M |
NBP vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NBP
DBVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| NovaBridge Bioscien… (NBP) | 100 | 8.9 | -91.1% |
| DBV Technologies S.… (DBVT) | 100 | 41.2 | -58.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NBP vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NBP leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
NBP
NovaBridge Biosciences
The Income Pick
NBP carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.25
- Rev growth -100.0%, EPS growth 74.7%
- -82.2% 10Y total return vs DBVT's -87.0%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Specific-Use Pick
In this particular matchup, DBVT is outpaced on most metrics by others in the set.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NBP | -100.0% revenue growth vs DBVT's -100.0% |
| Quality / Margins | NBP | 25.7% margin vs DBVT's 0.3% |
| Stability / Safety | NBP | Beta 1.25 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NBP | +149.4% vs DBVT's +110.4% |
| Efficiency (ROA) | NBP | -8.8% ROA vs DBVT's -89.0% |
NBP vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
Segment breakdown not available.
NBP vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNBPLAGGINGDBVT
DBVTDBV Technologies S.A.
2leads
NBPNovaBridge Biosciences
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NBP6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
DBVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
NBP1/1
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NBP and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | NBPNovaBridge Biosci… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$33M | -$112M |
| Net IncomeAfter-tax profit | -$25M | -$168M |
| Free Cash FlowCash after capex | $2M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +73.0% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — NBP and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | NBPNovaBridge Biosci… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $416M | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $407M | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -3.39x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 6.10x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — NBP and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
NBP leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
NBP delivers a -9.5% return on equity — every $100 of shareholder capital generates $-9 in annual profit, vs $-130 for DBVT. NBP carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), NBP scores 5/9 vs DBVT's 4/9, reflecting solid financial health.
| Metric | NBPNovaBridge Biosci… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -9.5% | -130.2% |
| ROA (TTM)Return on assets | -8.8% | -89.0% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -31.2% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.13x |
| Net DebtTotal debt minus cash | -$64M | -$172M |
| Cash & Equiv.Liquid assets | $68M | $194M |
| Total DebtShort + long-term debt | $4M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
NBP leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
DBVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DBVT five years ago would be worth $3,090 today (with dividends reinvested), compared to $374 for NBP. Over the past 12 months, NBP leads with a +149.4% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors DBVT at 6.2% vs NBP's -9.7% — a key indicator of consistent wealth creation.
| Metric | NBPNovaBridge Biosci… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | -48.0% | +4.9% |
| 1-Year ReturnPast 12 months | +149.4% | +110.4% |
| 3-Year ReturnCumulative with dividends | -26.5% | +19.7% |
| 5-Year ReturnCumulative with dividends | -96.3% | -69.1% |
| 10-Year ReturnCumulative with dividends | -82.2% | -87.0% |
| CAGR (3Y)Annualised 3-year return | -9.7% | +6.2% |
DBVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NBP and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
NBP is the less volatile stock with a 1.25 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. DBVT currently trades 76.3% from its 52-week high vs NBP's 32.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NBPNovaBridge Biosci… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 1.26x |
| 52-Week HighHighest price in past year | $6.79 | $26.18 |
| 52-Week LowLowest price in past year | $0.83 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +32.7% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 35.1 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 252K |
Evenly matched — NBP and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
NBP leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates NBP as "Buy" and DBVT as "Buy". Consensus price targets imply 305.4% upside for NBP (target: $9) vs 131.8% for DBVT (target: $46).
| Metric | NBPNovaBridge Biosci… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $46.33 |
| # AnalystsCovering analysts | 11 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
NBP leads this category, winning 1 of 1 comparable metric.
Key Takeaway
DBVT leads in 2 of 6 categories (Income & Cash Flow, Total Returns). NBP leads in 2 (Profitability & Efficiency, Analyst Outlook). 2 tied.
Best OverallNovaBridge Biosciences (NBP)Leads 2 of 6 categories
Loading custom metrics...
NBP vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NBP or DBVT a better buy right now?
Analysts rate NovaBridge Biosciences (NBP) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NBP or DBVT?
Over the past 5 years, DBV Technologies S.
A. (DBVT) delivered a total return of -69. 1%, compared to -96. 3% for NovaBridge Biosciences (NBP). Over 10 years, the gap is even starker: NBP returned -82. 2% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NBP or DBVT?
By beta (market sensitivity over 5 years), NovaBridge Biosciences (NBP) is the lower-risk stock at 1.
25β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 1% more volatile than NBP relative to the S&P 500. On balance sheet safety, NovaBridge Biosciences (NBP) carries a lower debt/equity ratio of 2% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — NBP or DBVT?
On earnings-per-share growth, the picture is similar: NovaBridge Biosciences grew EPS 74.
7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NBP or DBVT?
NovaBridge Biosciences (NBP) is the more profitable company, earning 0.
0% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NBP leads at 0. 0% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — NBP leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NBP or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NBP or DBVT better for a retirement portfolio?
For long-horizon retirement investors, NovaBridge Biosciences (NBP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
25)). Both have compounded well over 10 years (NBP: -82. 2%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NBP and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.